Indications
Elacestrant is an estrogen receptor antagonist. It is used to treat postmenopausal women and adult men whose advanced or metastatic breast cancer is ER-positive, HER2-negative and ESR1-mutated, and whose disease has progressed after at least one line of endocrine therapy.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Elacestrant is an estrogen receptor antagonist, and it works by binding to estrogen receptor-alpha (ERα). In ER-positive (ER+) HER2-negative (HER2-) breast cancer cells, it inhibited the cell proliferation driven by 17β-estradiol. This happened at concentrations that also caused the ERα protein to break down through the proteasomal pathway. Elacestrant showed antitumor activity both in vitro and in vivo. That included ER+ HER2- breast cancer models resistant to fulvestrant and to cyclin-dependent kinase 4/6 inhibitors, and models carrying estrogen receptor 1 gene (ESR1) mutations.
Pregnancy & Breastfeeding
Animal findings and the way Elacestrant works both point to a risk of harm to the baby if a pregnant woman takes it. There are no human data on its use in pregnancy, so the actual risk isn't known.
Nothing is known about whether elacestrant passes into human milk, whether it affects milk production, or what it might do to a breastfed child. Because the breastfed child could have serious adverse reactions, women who are breastfeeding should be advised not to breastfeed during treatment with Elacestrant and for 1 week after the last dose.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.